Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial

Viale, G. and Regan, M. M. and Dell'Orto, P. and Mastropasqua, M. G. and Maiorano, E. and Rasmussen, B. B. and MacGrogan, G. and Forbes, J. F. and Paridaens, R. J. and Colleoni, M. and Láng, I. and Thürlimann, B. and Mouridsen, H. and Mauriac, L. and Gelber, R. D. and Price, K. N. and Goldhirsch, A. and Gusterson, B. A. and Coates, A. S. and International Breast Cancer Study Groups, . (2011) Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Annals of oncology, Vol. 22, H. 10. pp. 2201-2207.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6004700

Downloads: Statistics Overview

Abstract

On average, aromatase inhibitors are better than tamoxifen when used as initial or sequential therapy for postmenopausal women with endocrine-responsive early breast cancer. Because there may be contraindications to their use based on side-effects or cost, we investigated subgroups in which aromatase inhibitors may be more or less important.

Faculties and Departments:	03 Faculty of Medicine > Bereich Medizinische Fächer (Klinik) > Onkologie 03 Faculty of Medicine > Departement Klinische Forschung > Bereich Medizinische Fächer (Klinik) > Onkologie
UniBasel Contributors:	Thürlimann, Beat
Item Type:	Article, refereed
Article Subtype:	Research Article
Publisher:	Oxford University Press
ISSN:	0923-7534
Note:	Publication type according to Uni Basel Research Database: Journal article
Last Modified:	27 Mar 2014 13:13
Deposited On:	27 Mar 2014 13:13

Repository Staff Only: item control page